...
首页> 外文期刊>Expert review of cardiovascular therapy >Randomized trials of PCIs versus CABG surgery: Why coronary stenting should remain the first choice of revascularization in non-diabetic patients and why the controversy is still present in diabetics
【24h】

Randomized trials of PCIs versus CABG surgery: Why coronary stenting should remain the first choice of revascularization in non-diabetic patients and why the controversy is still present in diabetics

机译:PCIs与CABG手术的随机试验:为什么在非糖尿病患者中冠状动脉支架置入术仍应是血运重建的首选,为什么在糖尿病患者中仍然存在争议

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Knowing the best revascularization option for diabetic patients with multiple vessel disease is a challenge without a definitive answer. There have been several randomized clinical trials and subsequent meta-analyses comparing current available technology trying to reach an exhaustive conclusion; comparisons between coronary artery bypass grafts and bare-metal stents, coronary artery bypass grafts and first generation drug-eluting stents and, most recently, first generation versus latest generation drug-eluting stents generated some interesting results. Information provided by pooled data from some of the most important randomized clinical cardiology trials from the last two decades have produced surprising results. The authors analyze these data to discuss the best therapeutic procedures for each patient.
机译:没有确定的答案,要知道患有多支血管疾病的糖尿病患者的最佳血运重建方案是一个挑战。已经有几项随机临床试验和随后的荟萃分析比较了试图得出详尽结论的当前可用技术。比较冠状动脉旁路移植物和裸金属支架,冠状动脉旁路移植物和第一代药物洗脱支架,以及最近的第一代与最新一代药物洗脱支架,产生了一些有趣的结果。最近二十年来一些最重要的随机临床心脏病学试验的汇总数据提供的信息产生了令人惊讶的结果。作者分析了这些数据,以讨论针对每个患者的最佳治疗程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号